help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2009-0126
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Rosen, M. D.
Right arrow Articles by Privalsky, M. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, M. D.
Right arrow Articles by Privalsky, M. L.
Molecular Endocrinology 23 (8): 1183-1192
Copyright © 2009 by The Endocrine Society

Thyroid Hormone Receptor Mutations Found in Renal Clear Cell Carcinomas Alter Corepressor Release and Reveal Helix 12 as Key Determinant of Corepressor Specificity

Meghan D. Rosen and Martin L. Privalsky

Department of Microbiology, University of California at Davis, Davis, California 95616

Address all correspondence and requests for reprints to: Martin L. Privalsky, Department of Microbiology, University of California at Davis, Davis, California 95616. E-mail: mlprivalsky{at}ucdavis.edu.

Thyroid hormone receptors (TRs) regulate multiple normal physiological and developmental pathways, whereas mutations in TRs can result in endocrine and neoplastic disease. A particularly high rate of TR mutations has been found in human renal clear cell carcinomas (RCCCs). We report here that the majority of these RCCC TR mutants tested are defective for transcriptional activation and behave as dominant-negative inhibitors of wild-type receptor function. Although several of the dominant-negative RCCC TR mutants are impaired for hormone binding, all fail to release from corepressors appropriately in response to T3, a trait that closely correlates with their defective transcriptional properties. Notably, many of these mutants exhibit additional changes in their specificity for different corepressor splice forms that may further contribute to the disease phenotype. Mapping of the relevant mutations reveals that the C-terminal receptor helix 12 is not simply a hormone-operated switch that either permits or prevents all corepressor binding, but is instead a selective gatekeeper that actively discriminates between different forms of corepressor even in the absence of T3.

NURSA Molecule Pages Link:

Nuclear Receptors:   TRα  |  TRβ  |  RXRα
Coregulators:   SRC-1  |  NCOR  |  SMRT
Ligands:   Thyroid hormone






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society